Louisiana Is Funding Ibogaine Trials With Money From Opioid Deaths. The Law Doesn't Require Anyone to Publish What They Find.
On August 1, 2026, Louisiana's Act 956 took effect without the governor's signature, creating a Psychedelic-Assisted Therapy Initiative inside the state's Department of Health. The money behind it comes from the settlement opioid manufacturers and distributors paid Louisiana for the overdose epidemic. That detail matters for what follows: this is money that exists because people died, directed now toward testing ibogaine, psilocybin, and MDMA in academic health centers.
A detailed regulatory analysis published by Odette Alina Hauke, a regulatory scientist, in Psychedelic State(s) of America, lays out something specific and verifiable: across four printed versions of the bill, two legislative chambers, and a conference committee, eighteen words related to publishing results never appear. Not publish. Not published. Not disclosure. Not peer review. Not journal. Not transparent. Not one of them, not once.
The Law Is Actually More Careful Than Texas's, Which Is What Makes the Silence Notable
We've covered Texas's own ibogaine research law here before. The comparison matters because Louisiana's statute is, on paper, the more rigorous of the two. Where Texas's Chapter 491 doesn't use the words adverse event, monitoring, or institutional review board at all, Louisiana's Part IX requires every participating study to document a federally authorized pathway (an investigational new drug application or expanded access), a DEA Schedule I research registration, institutional review board approval, and a detailed safety monitoring plan covering medical and psychiatric screening, on-site emergency response, adverse event reporting timelines, and predefined rules for stopping a study.
Louisiana also asked for less money. Both states' laws route commercial proceeds from any resulting consortium to the same destinations, ending in "the remainder to the members of the consortium." Texas set the state's cut at not less than 20 percent. Louisiana set its cut at 2.5 percent of net sales as a running royalty, an eighth of Texas's figure, calculated a different way entirely. According to Hauke's analysis, this was not an oversight. A Senate committee version of the bill originally carried Texas's 20 percent figure verbatim. A House floor amendment, adopted May 7, 2026, deleted it and substituted the 2.5 percent royalty instead.
The point isn't that Louisiana undervalued its position, carelessly. It's that a legislature careful enough to import Texas's cardiac-risk and IRB language, and careful enough to specifically renegotiate its revenue share down, never once inserted a requirement that the trial results themselves be made public. The rigor applied everywhere except there.
What Happened on the House Floor
The bill's history, as documented in the legislative record, is specific. Senator Patrick McMath's original filed version ran 888 words with no revenue-sharing or intellectual property language at all. It read as a straightforward research authorization. The Senate Committee on Health and Welfare added commercial rights provisions and the 20 percent state share, and the full Senate passed that version 37 to 0 on April 15, 2026.
The House then rewrote it. Representative Neil Riser's floor amendments, adopted May 7, did five things: cut the state's share to 2.5 percent, changed language from "shall" file for FDA breakthrough designation to "may," directed the department to treat opioid settlement money as leverage for matching federal funds, added coordination requirements with other states, and added MDMA to the list of covered drugs. The House passed this version 97 to 0. The Senate initially rejected the House's changes 34 to 1 on May 18. A conference committee then recommended adopting Riser's amendments anyway, and both chambers approved the compromise, the House by 97 to 0 again on May 31.
Four drafts. Two chambers. A conference committee. The analysis is specific that transparency language was never proposed at any stage, by anyone, for anyone to strike.
The Money Itself Has a Structural Gap
Separately from the legislation, Hauke's reporting identifies a practical problem with how the underlying opioid settlement money is distributed. Louisiana has 64 parishes. Under the 2021 memorandum of understanding that governs the settlement funds (there is no actual statute governing this money, only the MOU), only 12 entities, three large parishes paid directly plus nine regional Lead Parishes, hold settlement funds of their own. Act 956 directs academic health centers to coordinate with parishes to spend this money enrolling patients. For the other 52 parishes, there's no parish-level fund to coordinate with.
There is also no direct state appropriation for the initiative. The state's own fiscal office scored the program as increasing costs by "an indeterminable but minimal amount," and the law instructs the department to use the opioid settlement money itself as matching funds to unlock federal dollars, the same approach Texas tried and stalled on when no pharmaceutical partner qualified as a match.
One Place in the Paperwork Does Require Publishing, and It Isn't About Results
The analysis notes something precise here. The memorandum of understanding governing the settlement money does require an annual published report, but only of where the dollars went: the recipient, the amount awarded, the program funded, and disbursement terms. That reporting duty exists and is specific. It simply was never written to cover what any funded trial actually finds. As Hauke puts it, it's a receipts clause, not a results clause.
The gap isn't that nobody asked for transparency anywhere in this system. Louisiana's legislature, in the same 2026 session, separately asked its Legislative Auditor to report on how opioid settlement money overall is being spent, and urged regulators to impose new reporting duties on sheriffs. The state was actively worried about settlement-money accountability in general, in the exact months it created a research program funded by that same money, without building in the one accountability mechanism that would tell the public whether the ibogaine research itself worked.
What Could Still Change This, and the Deadline That Matters
The analysis identifies a specific, still-open point of leverage. Act 956 requires participating academic health centers to file annual progress reports starting January 1, 2027, compiled by the Department of Health into a report to the legislature by March 1. Critically, the statute gives the department, not the legislature, full discretion over what data that report must contain: "The Louisiana Department of Health shall determine the data required for inclusion in the report." No rulemaking process is required, which means no formal notice-and-comment period stands in the way of the department deciding this now, before the first report comes due.
There's also a federal deadline that intersects with this directly. The FDA opened a public docket in October 2026 (the same docket we submitted our own comment to), asking for input on trial design, dose selection, safety monitoring, and study-stopping rules for ibogaine research specifically. Reuters reported that this follows a $50 million federal commitment from an April 2026 executive order, and that FDA has separately reaffirmed the drug carries serious risks including life-threatening arrhythmias. That docket closes November 20, 2026. The standards it sets, including whether submitted data must follow a common format researchers can actually combine across states, will shape whether a Louisiana trial cohort and a Texas trial cohort produce comparable results or two incompatible data sets that happen to study the same drug.
Why This Matters If You're Actually Considering Ibogaine Treatment
None of this changes what's available to someone seeking ibogaine treatment today. These are state-funded research programs working toward FDA approval, not new treatment access. If you're researching ibogaine right now, your options remain what they've been: clinics outside the United States, mostly in Mexico, operating under a very different accountability structure than a state-funded FDA trial.
But the gap documented here matters for a different reason. Government-funded trials are the most credible path toward wider, insurance-covered, physician-prescribed ibogaine treatment in the US. If Louisiana's and Texas's research produces real safety and efficacy data that the public and other researchers can actually see, it strengthens the evidence base this entire field badly needs. If it produces results that stay inside the academic health centers that ran the trials, or inside a licensing deal nobody outside the consortium gets to review, then the public that funded this research may never get to see what it found. Given that Louisiana paid for this with money that exists because of opioid deaths, that distinction is not a technicality.
We'll be watching what the Louisiana Department of Health decides to require in that January 2027 report, and whether anyone takes up Hauke's suggestion to weigh in on FDA's docket before November 20. If either produces something concrete, we'll update this page.